An interventional study of Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD in Cardiovascular Diseases, Hypertension and Diabetes, sponsored by Tulane University. Active, not recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Tulane University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Hypertension by Tulane University — 2 open to participants now, 7 under way, none of them phase 3. Hypertension · Tulane University.
Among the 17 studies in Hypertension by Tulane University, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2023, is one of 13 with no phase, and was the 14th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →2 of the 17 studies in Hypertension by Tulane University are open now, in 1 country. Recruiting first, the newest first:
Tulane University · Sites in United States
Ages 18+
Tulane University · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 1973; this study’s year is marked. 3 started in 2023.
This study's enrollment of 812 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 1,176 across the 15 interventional studies, 5,874 across the 2 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tulane University is the lead sponsor of 96 studies on the registry; 23 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.
3 of the studies in Hypertension by Tulane University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183763Tulane UniversityMedication Adherence Program | 2027-04-30 |
| NCT06133322Tulane UniversityBlood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) | 2027-06-30 |
| NCT06065098Tulane UniversityChurch-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Hypertension by Tulane University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cardiovascular disease (CVD) is the leading cause of death in the US general population. Although CVD mortality rates declined for both Black and White populations during the past two decades, they are still higher in Black adults than White adults. There are also persistent disparities in CVD risk factors with higher prevalence of obesity, hypertension, and diabetes in Black compared to White populations. In addition, CVD and risk factors are more prevalent in the residents of Louisiana compared to the US general population. The Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health (CHERISH) study will use a church-based community health worker (CHW)-led multifaceted intervention to address racial inequities in CVD risk factors in predominantly Black communities in New Orleans, Louisiana. The primary aim of the CHERISH study is to compare the impact of two implementation strategies - a CHW-led multifaceted strategy and a group-based education strategy - for delivering interventions recommended by the 2019 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on the Primary Prevention of Cardiovascular Disease on implementation and clinical effectiveness outcomes in predominantly Black church community members over 18 months.
Louisiana residents, especially African Americans, bear a disproportionately high burden of CVD. In the CHERISH cluster randomized trial, we will compare the impact of two implementation strategies - a CHW-led multifaceted strategy and a group-based education strategy - for delivering interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease on implementation and clinical effectiveness outcomes in Black community members over 18 months. The CHERISH study utilizes an effectiveness-implementation hybrid design to: (1). test the effectiveness of a CHW-led church-based multifaceted implementation strategy for reducing estimated CVD risk over 18 months among African Americans at high risk for CVD, and (2). assess the implementation outcomes (acceptability, adaptation, adoption, feasibility, fidelity, penetrance, cost-effectiveness, and sustainability) simultaneously. The Exploration, Preparation, Implementation, Sustainment (EPIS) framework has guided the development and evaluation of the multifaceted implementation strategy, which includes CHW-led health coaching on lifestyle changes and medication adherence; healthcare delivery in community; church-based exercise and weight loss programs; self-monitoring of blood pressure (BP); and provider education and engagement. The CHW-led church-based intervention will provide strong social support and tackle multiple social determinants of CVD disparities. The primary effectiveness outcome is change in the estimated 10-year risk for atherosclerotic CVD (ASCVD) using the ACC/AHA Pooled Cohort Equations. The primary implementation outcome is a fidelity summary score for key implementation strategy components during the 18-month intervention. Our study has 96% statistical power to detect a slope difference of 0.83% in 10-year ASCVD risk over 18 months using a 2-sided significance level of 0.05. We will recruit 806 participants (17.5 per church) aged ≥40 years who have \<3 ideal cardiovascular health matrices and randomly assign 23 churches to intervention and 23 to control; we will implement the multifaceted intervention program; we will follow-up participants and collect data on effectiveness and implementation outcomes at 6, 12, and 18 months; we will evaluate the sustainability of the intervention at 6 months post-intervention; and we will perform intention-to-treat analyses and disseminate and scale-up the proven-effective implementation strategy. The proposed study will generate evidence on the effectiveness, implementation, and sustainability of the multifaceted intervention aimed at eliminating CVD disparities in predominantly African American communities in the US.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
This study's enrollment of 812 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Browse Hypertension studies →Tulane University is the lead sponsor of 96 studies on the registry; 23 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.
Compared within Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals with three or more CVD risk factors (out of seven):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individual coaching sessions; healthcare navigation; healthcare at community settings; church-based nutrition education and exercise programs; and self-monitoring of BP.
Behavioral: Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD
Group-based education sessions; information on primary care physicians; and instruction on self-monitoring of BP.
Behavioral: Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD
The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension, diabetes, and hypercholesterolemia.
Difference in change in estimated atherosclerotic cardiovascular disease (ASCVD) risk score
The ACC/AHA ASCVD risk score will be calculated using the pooled population cohort equation based on age (years), total cholesterol (mg/dL), high-density lipoprotein (HDL)-cholesterol (mg/dL), antihypertensive medication use, systolic BP (mmHg), current smoking status, and diabetes status. The risk score ranges from 0% to 100%.
Time frame: Measured from baseline to 18 months
Fidelity summary score
The fidelity summary score is composed of the following key implementation strategy components: proportion of assigned health education sessions attended in all participants, proportion of assigned discussion sessions attended in all participants, proportion of recommended minutes of physical activity completed in all participants, proportion of days per week that fruits/vegetables are eaten as recommended in all participants, proportion of recommended home BP monitoring completed in patients with hypertension, proportion of required provider visits attended in all patients, and proportion of antihypertensive, antidiabetic, and statin medications taken in patients with hypertension or diabetes, or those who are eligible for statin treatment, respectively.
Time frame: Measured at 6, 12, and 18 months
Difference in change in systolic blood pressure level
The change in systolic blood pressure level from baseline to 18 months between the two arms.
Time frame: Measured from baseline to 18 months
Difference in change in diastolic blood pressure level
The change in diastolic blood pressure level from baseline to 18 months between the two arms.
Time frame: Measured from baseline to 18 months
Difference in change in total cholesterol level
The change in total cholesterol level from baseline to 18 months between the two arms.
Time frame: Measured from baseline to 18 months
Difference in change in low-density lipoprotein (LDL) cholesterol level
The difference in the change in LDL cholesterol level between the two arms.
Time frame: Measured from baseline to 18 months
Difference in change in fasting glucose level
The change in fasting glucose level from baseline to 18 months between the two arms.
Time frame: Measured from baseline to 18 months
Difference in change in hemoglobin A1c level
The change in hemoglobin A1c level from baseline to 18 months between the two arms
Time frame: Measured from baseline to 18 months
Difference in change in body weight
The change in body weight from baseline to 18 months between the two arms.
Time frame: Measured from baseline to 18 months
Appropriateness
Percentage of participants, community health workers, providers, and church administrators who reply that the intervention is appropriate (good perceived fit). The outcome will be measured by survey question.
Time frame: Prior to baseline
Adoption (provider)
Percentage of invited providers attending training sessions. Measured by study administrative data.
Time frame: At baseline
Adoption (church)
Percentage of churches adopting the intervention program. Measured by study administrative data.
Time frame: At baseline
Feasibility to participant, community health worker, provider and churches
Percentage of participants, community health worker, providers, and church administrators who reply that the intervention is feasible (actual fit, suitability). Measured by survey and study administrative data.
Time frame: Baseline
Acceptability
Percentage of participants, community health worker, providers, and church administrators who reply that the intervention is acceptable (satisfactory). Measured by survey.
Time frame: Measured at baseline, 6, 12, and 18 months
Penetrance (Participants)
Percentage of enrolled participants receiving assigned intervention. Measured by study administrative data.
Time frame: Measured at baseline, 6, 12, and 18 months
Costs
Implementation costs related to intervention and healthcare but not to study data collection. Measured by study administrative data.
Time frame: Baseline, 6, 12, and 18 months
Health Coaching Session Fidelity (community health worker-led strategy group)
Percentage of health coaching sessions conducted. Measured by study administrative data.
Time frame: Measured at 6, 12, and 18 months
Nutrition Education Session Fidelity (community health worker-led strategy group)
Percentage of nutrition education sessions organized. Measured by study administrative data.
Time frame: Measured at 6, 12, and 18 months
Exercise Session Fidelity (community health worker-led strategy group)
Percentage of exercise sessions organized. Measured by study administrative data.
Time frame: Measured at 6, 12, and 18 months
Health Care Appointment Fidelity (community health worker-led strategy group)
Percentage of health care visit appointments made. Measured by study administrative data.
Time frame: Measured at 6, 12, and 18 months
Penetrance (Providers)
Percentage of trained providers delivering protocol-based care. Measured by study administrative data.
Time frame: Measured at baseline, 6, 12, and 18 months
Penetrance (Educators)
Percentage of trained CHWs or providers and health educators delivering health coaching. Measured by study administrative data.
Time frame: Measured at baseline, 6, 12, and 18 months
Sustainability (Churches)
Percentage of churches continuing the intervention program and individual components. Measured by 6-month post-intervention survey.
Time frame: Measured at 24 months
Sustainability (Participants)
Percentage of participants maintaining ideal cardiovascular health metrics, healthy lifestyle components, and adherence to medications. Measured by 6-month post-intervention survey and examination.
Time frame: Measured at 24 months
Difference in proportion of those receiving statin treatment who are eligible
Percentage of those receiving statin treatment who are eligible between the two arms over 18 months. Measured by survey data.
Time frame: Measured from baseline to 18 months
Difference in proportion of those who cease smoking of those who are current smokers at baseline
Percentage of those who cease smoking of those who are current smokers at baseline between the two arms over 18 months. Measured by survey data.
Time frame: Measured from baseline to 18 months
Difference in medication adherence
Percentage of self-reported medication adherence over 18 months. Self-reported medication adherence will be assessed using an medication adherence questionnaire.
Time frame: Measured from baseline to 18 months
Difference in quality of life (QoL)
The difference in QoL between the two arms over 18 months. QoL will be assessed using the SF-12 questionnaire. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Time frame: Measured from baseline to 18 months
Plan to share: Yes — Our study data sharing plan will comply with all NIH policies for data sharing. Data sharing will be executed through the centralized NIH data repository and will be implemented in a timely manner. The study data, including data from baseline and follow-up visits, will be prepared for transmission to the NHLBI data repository - the Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). The datasets will be submitted to the NHLBI no later than three years after the end of the final participant follow-up or two years after the main paper of the trial has been published, whichever comes first. The NHLBI will review the submitted data prior to release. These data will be free of identifiers that allow identification of individual research participants either directly or through "deductive disclosure." In addition, we will offer, through our publicly accessible website, opportunities for outside investigators to collaborate with us using complete study data.
Supporting information: Study protocol, Statistical analysis plan
Time frame: No later than three years after the end of the final participant follow-up or two years after the main paper of the trial has been published, whichever comes first
Started Sep 2023 (actual). Primary completion is estimated for Aug 2027, 47 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 47 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tulane University